POINT-OF-CARE MEASUREMENT OF INFLIXIMAB AND ADALIMUMAB TROUGH LEVELS BY THE FLUORESCENCE RESONANCE ENERGY TRANSFER (FRET) ASSAY

被引：0
|
作者：
Cerna, Karin
Kastylova, Kristyna
Lukas, Milan
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
EP1285
引用
收藏
页码：S1086 / S1087
页数：2
相关论文
共 50 条
  • [1] Point-of-care measurement of infliximab and adalimumab trough levels by the fluorescence resonance energy transfer (FRET) assay
    Cerna, K.
    Kastylova, K.
    Sebek, P.
    Luxova, S.
    Lukas, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I217 - I218
  • [2] Time-resolved fluorescence resonance energy transfer assay for point-of-care testing of urinary albumin
    Qin, QP
    Peltola, O
    Pettersson, K
    CLINICAL CHEMISTRY, 2003, 49 (07) : 1105 - 1113
  • [3] Performance of the BUHLMANN Quantum Blue® Infliximab point-of-care assay dedicated for therapeutic drug monitoring of serum infliximab trough levels
    Schuster, T.
    Keller, E.
    Krauchi, S.
    Bantleon, F.
    Weber, J.
    Schneider, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S215 - S215
  • [4] Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result
    Brosi, L.
    Reinhard, C.
    Anchling, L.
    Afonso, J.
    Schuster, T.
    Gerhold, C. B.
    Ricken, B.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I308 - I309
  • [5] Fluorescence resonance energy transfer (FRET) measurement by gradual acceptor photobleaching
    Van Munster, EB
    Kremers, GJ
    Adjobo-Hermans, MJW
    Gadella, TWJ
    JOURNAL OF MICROSCOPY, 2005, 218 : 253 - 262
  • [6] Fluorescence resonance energy transfer (FRET) as biomarkers
    Paul, Ripa
    Suklabaidya, Sudip
    Hussain, Syed Arshad
    MATERIALS TODAY-PROCEEDINGS, 2021, 46 : 6301 - 6303
  • [7] Comparative analysis of fluorescence resonance energy transfer (FRET) and proximity ligation assay (PLA)
    Maria-Magdalena Mocanu
    Timea Varadi
    Janos Szoellovsi
    Peter Nagy
    PROTEOMICS, 2011, 11 (10) : 2063 - 2070
  • [8] Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
    Marsilio, I.
    Maniero, D.
    Lorenzon, G.
    Rigo, A.
    Cardin, R.
    Facchin, S.
    Barberio, B.
    D'Inca, R.
    Zingone, F.
    Bahur, B.
    Bray, K. B.
    Savarino, E. V.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S353 - S353
  • [9] COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Marsilio, I
    Maniero, D.
    Lorenzon, G.
    Rigo, A.
    Cardin, R.
    Facchin, S.
    Barberio, B.
    D'Inca, R.
    Zingone, F.
    Bahur, B.
    Bray, K.
    Savarino, E.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S158 - S158
  • [10] COMPARATIVE ASSESSMENT OF INFLIXIMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Maniero, D.
    Lorenzon, G.
    Marsilio, I
    Rigo, A.
    Cardin, R.
    Facchin, S.
    Barberio, B.
    D'Inca, R.
    Zingone, F.
    Bahur, B.
    Bray, K.
    Savarino, E., V
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S162 - S162
12345